<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526928</url>
  </required_header>
  <id_info>
    <org_study_id>CO-1686-008</org_study_id>
    <nct_id>NCT01526928</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)
      that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while
      sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK)
      and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or
      recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of
      rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer remains the most common cancer worldwide with non-small cell lung cancer
      accounting for 85% of cases. Cytotoxic chemotherapy has been the mainstay of patients with
      NSCLC; however, survival rates remain low and toxicity is significant. Molecularly targeted
      therapies have proven to be superior to chemotherapy for NSCLC patients whose tumors have
      mutations in EGFR. Recent studies have established tyrosine kinase inhibitors (TKIs) as the
      gold standard for treating EGFR-mutation-positive NCSLC. However, patients on TKIs eventually
      progress, and in approximately 50% of cases, progression is due to development of an
      additional mutation called T790M. There are currently no approved therapies for patients who
      progress on TKIs. Rociletinib may provide an effective therapy for a patient population with
      few alternative treatment options. Nonclinical data demonstrate that rociletinib inhibits
      T790M. It is anticipated that rociletinib may promote cell death in tumor cells with the
      T790M mutation, thus providing possible therapeutic benefit in patients who have developed
      T790M-mediated resistance to first generation TKIs.

      This is a two-part, open-label study of oral rociletinib administered daily in previously
      treated NSCLC patients who have documented evidence of an activating mutation in the EGFR
      gene and have failed treatment with an EGFR inhibitor such as erlotinib, gefitinib or
      afatinib.

      This study will include 2 parts:

      Phase 1: Dose-escalation Period with 21-day cycles; optional Treatment Extension Period
      starting on Day 22

      Phase 2: Evaluation of activity and safety in patients with the T790M EGFR mutation who have:

      Cohort A - Progressed on EGFR directed therapy (irrespective of the number and order of
      previous lines of NSCLC therapy) or Cohort B - Progression on the first single agent EGFR
      directed therapy received and also had no more than one previous line of chemotherapy or
      Cohort C - Patients with discordance between local (T790M positive) and central (T790M
      negative) T790M results, or had no central test result due to inadequacy of the tissue
      specimen and known to be T790M positive by local test
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 27, 2012</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 3, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of T790M Positive Patients With Confirmed Response Per Investigator</measure>
    <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 42 months</time_frame>
    <description>Percentage of patients with a T790M mutation (determined by central lab) with a best overall confirmed response of partial response (PR) or complete response (CR) recorded from the start of the treatment until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm. Partial Response (PR),at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DOR) in T790M Positive Patients According to RECIST Version 1.1 as Determined by Investigator Assessment</measure>
    <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 36 months</time_frame>
    <description>Duration of Response in patients with a T790M mutation (determined by central lab) with confirmed response per investigator. The DOR for complete response (CR) and partial response (PR) was measured from the date that any of these best responses is first recorded until the first date that progressive disease (PD) is objectively documented. For patients who continue treatment post-progression, the first date of progression was used for the analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) Incidence</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 1 Day 21</time_frame>
    <description>The number of Phase 1 patients who experienced dose limiting toxicities after one cycle (21 days) of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Determined by Investigator Assessment</measure>
    <time_frame>Cycle 1 Day 1 to date of death, assessed up to 42 months</time_frame>
    <description>Overall survival was calculated as 1+ the number of days from the first dose of study drug to death due to any cause. Patients without a documented date of death were censored on the date the patient was last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)</measure>
    <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 42 months</time_frame>
    <description>Progression-free survival was calculated as the number of days from the date of the first dose of study drug to the date of disease progression or death due to any cause + 1. Patients without a documented event of disease progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment) or date of first dose of study drug if no tumor assessments have been performed. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile of Rociletinib - Cmax</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
    <description>Cmax = maximum concentration following administration of rociletinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile of Rociletinib - Tmax</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
    <description>Tmax = time to maximum concentration following administration of rociletinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile of Rociletinib - AUC 0-24</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
    <description>AUC 0-24 = area under the curve from 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Profile of Rociletinib - T 1/2</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
    <description>T 1/2 = elimination half-life following administration of rociletinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on PK of Rociletinib - Cmax</measure>
    <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
    <description>Cmax = maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on PK of Rociletinib - Tmax</measure>
    <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
    <description>Tmax = time to maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on PK of Rociletinib - AUC 0-24</measure>
    <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
    <description>AUC 0-24 = area under the curve from 0 to 24 hours. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on PK of Rociletinib - C24</measure>
    <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
    <description>C24 = rociletinib plasma concentration at 24 hours post the morning dose. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect on PK of Rociletinib - T 1/2</measure>
    <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
    <description>T 1/2 = elimination half-life following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF Values Post Baseline by Daily Dose</measure>
    <time_frame>Screening to End of Treatment, up to approximately 42 months</time_frame>
    <description>Frequency of QT interval prolongation by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF Value Change From Baseline</measure>
    <time_frame>Screening to End of Treatment, up to approximately 42 months</time_frame>
    <description>QTcF value change from baseline by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), Duration of Response (DOR) and Progression-Free Survival (PFS) Per RECIST Version 1.1 as Determined by IRR</measure>
    <time_frame>Cycle 1 Day 1 to End of Treatment / End of Follow-up</time_frame>
    <description>Objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) per RECIST Version 1.1 as determined by independent radiology review (IRR)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Locally Advanced or Metastatic Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Rociletinib &lt;900 mg BID FB formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rociletinib 900 mg BID FB formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib free base (FB) dose 900 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rociletinib 500 mg BID HBr formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rociletinib 625 mg BID HBr formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rociletinib 750 mg BID HBr formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rociletinib 1000 mg BID HBr formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib &lt;900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles</description>
    <arm_group_label>Rociletinib &lt;900 mg BID FB formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles</description>
    <arm_group_label>Rociletinib 900 mg BID FB formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib 500 mg BID HBr will be administered daily</description>
    <arm_group_label>Rociletinib 500 mg BID HBr formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib 625 mg BID HBr will be administered daily</description>
    <arm_group_label>Rociletinib 625 mg BID HBr formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib 750 mg BID HBr will be administered daily</description>
    <arm_group_label>Rociletinib 750 mg BID HBr formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib 1000 mg BID HBr will be administered daily</description>
    <arm_group_label>Rociletinib 1000 mg BID HBr formulation</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria -

        All patients must meet the following inclusion criteria:

          1. Metastatic or unresectable locally advanced NSCLC

          2. Evidence of a tumor with one or more EGFR mutations excluding exon 20 insertion

          3. Biopsy of either primary or metastatic tumor tissue within 60 days of dosing

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          5. Minimum age of 18 years

          6. Adequate hematological and biological function

          7. Written consent on an IRB/IEC-approved Informed Consent Form (ICF) prior to any
             study-specific evaluation

        Phase 2 Cohorts must also meet the following inclusion criteria:

          -  Disease progression confirmed by radiologic assessment while on treatment with EGFR-
             TKI Or

          -  Disease progression confirmed by radiologic assessment while on treatment with the
             first single agent EGFR TKI and

          -  Documented evidence of T790M mutation in EGFR following disease progression on the
             first single agent EGFR TKI.

          -  Measureable disease according to RECIST Version 1.1

        Exclusion Criteria -

        Any of the following criteria will exclude patients from study participation:

          1. Documented evidence of an Exon 20 insertion activating mutation in the EGFR gene

          2. Active second malignancy

          3. Known pre-existing interstitial lung disease

          4. Patients with Leptomeningeal carcinomatosis are excluded. Other CNS metastases are
             only permitted if treated, asymptomatic and stable (not requiring steroids for at
             least 4 weeks prior to start of study treatment).

          5. Treatment with prohibited medications less than or equal to 14 days prior to treatment
             with rociletinib

          6. Patients who are currently receiving treatment with any medications that have the
             potential to prolong the QT interval and the treatment cannot be either discontinued
             or switched to a different medication before starting rociletinib

          7. Prior treatment with rociletinib or other drugs that target T790M positive mutant EGFR
             with sparing of wild type EGFR

          8. Certain cardiac abnormalities or history

          9. Non-study related surgical procedures less than or equal to 7 days prior to
             administration of rociletinib

         10. Females who are pregnant or breastfeeding

         11. Refusal to use adequate contraception for fertile patients (females and males) for 12
             weeks after the last dose of rociletinib

         12. Presence of any serious or unstable concomitant systemic disorder incompatible with
             the clinical study

         13. Any other reason the investigator considers the patient should not participate in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Health System</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Hematology and Oncology Medical Group, Inc.</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovations</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center/UMHC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center, The Duchossois Center for Advanced Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Care Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence CancerCenter Oncology and Hematology Care Clinic-Eastside Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPMC), Div. of Medical Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex 2</city>
        <state>Provence Alpes COTE D'azur</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <state>Rhone-alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 04</city>
        <state>Rhone-alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen Cedex 05</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Créteil</name>
      <address>
        <city>Creteil cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med University Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <results_first_submitted>June 11, 2019</results_first_submitted>
  <results_first_submitted_qc>December 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2020</results_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>lung</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>epidermal growth factor receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>T790M</keyword>
  <keyword>CO-1686</keyword>
  <keyword>unresectable</keyword>
  <keyword>recurrent</keyword>
  <keyword>EGFR-directed therapy</keyword>
  <keyword>irreversible EGFR inhibitor</keyword>
  <keyword>TIGER</keyword>
  <keyword>Rociletinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01526928/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01526928/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 612 patients who received rociletinib—111 enrolled in Phase 1 and 501 enrolled in Phase 2. The Phase 1 component of the study was conducted at 8 study sites in the US, Australia, and France. Phase 2 was conducted at 49 study sites in the US, France, Poland, and Australia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rociletinib &lt;900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID). FB doses tested ranged from 150 mg once a day (QD) up to 900 mg twice a day (BID). This arm also includes a 400 mg three times a day (TID) dose. Rociletinib FB capsules were administered in Phase 1 only (until November 2013) and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day treatment cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
        <group group_id="P2">
          <title>Rociletinib 900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose 900 mg twice a day (BID). Rociletinib FB capsules were administered in Phase 1 only (until November 2013) and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day treatment cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
        <group group_id="P3">
          <title>Rociletinib 500 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID). Rociletinib hydrobromide (HBr) tablets were administered in Phase 1 (starting in August 2013) and in all Phase 2 cohorts and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
        <group group_id="P4">
          <title>Rociletinib 625 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID). Rociletinib hydrobromide (HBr) tablets were administered in Phase 1 (starting in August 2013) and in all Phase 2 cohorts and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
        <group group_id="P5">
          <title>Rociletinib 750 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID). Rociletinib hydrobromide (HBr) tablets were administered in Phase 1 (starting in August 2013) and in all Phase 2 cohorts and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
        <group group_id="P6">
          <title>Rociletinib 1000 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID). Rociletinib hydrobromide (HBr) tablets were administered in Phase 1 (starting in August 2013) and in all Phase 2 cohorts and were provided in 50 mg or 150 mg white capsules. Patients were instructed to take each dose with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Patients received rociletinib in 21-day cycles and were treated until there was progression by RECIST v1.1, clinical tumor progression, or unacceptable toxicity, or other discontinuation criteria were met. Patients could opt to continue to receive treatment with rociletinib following radiographic progression as outlined in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of NSCLC with EGFR-TKIs if the patient provided consent, and the investigator and sponsor approved.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="209"/>
                <participants group_id="P4" count="245"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Phase 1</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Phase 2</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="191"/>
                <participants group_id="P4" count="228"/>
                <participants group_id="P5" count="82"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="209"/>
                <participants group_id="P4" count="245"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="182"/>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rociletinib &lt;900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
        </group>
        <group group_id="B2">
          <title>Rociletinib 900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
        </group>
        <group group_id="B3">
          <title>Rociletinib 500 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
        </group>
        <group group_id="B4">
          <title>Rociletinib 625 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
        </group>
        <group group_id="B5">
          <title>Rociletinib 750 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
        </group>
        <group group_id="B6">
          <title>Rociletinib 1000 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="209"/>
            <count group_id="B4" value="245"/>
            <count group_id="B5" value="95"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="612"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="11.54"/>
                    <measurement group_id="B2" value="58.9" spread="8.37"/>
                    <measurement group_id="B3" value="63.6" spread="11.45"/>
                    <measurement group_id="B4" value="62.5" spread="11.14"/>
                    <measurement group_id="B5" value="61.5" spread="11.82"/>
                    <measurement group_id="B6" value="65.2" spread="5.53"/>
                    <measurement group_id="B7" value="62.5" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="184"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="495"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="368"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Diagnosis of NSCLC (months)</title>
          <population>Data not available for one participant in the 500 mg BID Hbr treatment group.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="208"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="29.2"/>
                    <measurement group_id="B2" value="45.4" spread="31.94"/>
                    <measurement group_id="B3" value="36.7" spread="25.81"/>
                    <measurement group_id="B4" value="36.7" spread="31.41"/>
                    <measurement group_id="B5" value="37.6" spread="29.97"/>
                    <measurement group_id="B6" value="47.4" spread="27.03"/>
                    <measurement group_id="B7" value="37.4" spread="29.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T790M Status ( Determined by Central Lab)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="480"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of CNS Metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Therapies</title>
          <units>Therapies</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.65"/>
                    <measurement group_id="B2" value="3.7" spread="1.66"/>
                    <measurement group_id="B3" value="2.6" spread="1.74"/>
                    <measurement group_id="B4" value="2.8" spread="1.91"/>
                    <measurement group_id="B5" value="2.9" spread="2.11"/>
                    <measurement group_id="B6" value="3.8" spread="2.04"/>
                    <measurement group_id="B7" value="2.9" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous TKI Therapies</title>
          <units>Therapies</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="209"/>
                    <count group_id="B4" value="245"/>
                    <count group_id="B5" value="95"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="612"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.77"/>
                    <measurement group_id="B2" value="2.3" spread="1.48"/>
                    <measurement group_id="B3" value="1.5" spread="0.87"/>
                    <measurement group_id="B4" value="1.6" spread="0.77"/>
                    <measurement group_id="B5" value="1.6" spread="0.86"/>
                    <measurement group_id="B6" value="1.8" spread="0.75"/>
                    <measurement group_id="B7" value="1.6" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of T790M Positive Patients With Confirmed Response Per Investigator</title>
        <description>Percentage of patients with a T790M mutation (determined by central lab) with a best overall confirmed response of partial response (PR) or complete response (CR) recorded from the start of the treatment until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm. Partial Response (PR),at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.</description>
        <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 42 months</time_frame>
        <population>Intent-to-treat: All randomized patients who are confirmed by central lab to be T790M positive</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of T790M Positive Patients With Confirmed Response Per Investigator</title>
          <description>Percentage of patients with a T790M mutation (determined by central lab) with a best overall confirmed response of partial response (PR) or complete response (CR) recorded from the start of the treatment until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt; 10 mm. Partial Response (PR),at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.</description>
          <population>Intent-to-treat: All randomized patients who are confirmed by central lab to be T790M positive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="188"/>
                <count group_id="O4" value="176"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Response (DOR) in T790M Positive Patients According to RECIST Version 1.1 as Determined by Investigator Assessment</title>
        <description>Duration of Response in patients with a T790M mutation (determined by central lab) with confirmed response per investigator. The DOR for complete response (CR) and partial response (PR) was measured from the date that any of these best responses is first recorded until the first date that progressive disease (PD) is objectively documented. For patients who continue treatment post-progression, the first date of progression was used for the analysis.</description>
        <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 36 months</time_frame>
        <population>The DOR was measured only in T790M positive patients with a Complete Response (CR) or Partial Response (PR). There were no responders in the Rociletinib &lt;900 mg BID treatment group so DOR is not applicable and thus not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) in T790M Positive Patients According to RECIST Version 1.1 as Determined by Investigator Assessment</title>
          <description>Duration of Response in patients with a T790M mutation (determined by central lab) with confirmed response per investigator. The DOR for complete response (CR) and partial response (PR) was measured from the date that any of these best responses is first recorded until the first date that progressive disease (PD) is objectively documented. For patients who continue treatment post-progression, the first date of progression was used for the analysis.</description>
          <population>The DOR was measured only in T790M positive patients with a Complete Response (CR) or Partial Response (PR). There were no responders in the Rociletinib &lt;900 mg BID treatment group so DOR is not applicable and thus not reported.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.0" lower_limit="190.0" upper_limit="713.0"/>
                    <measurement group_id="O2" value="275.0" lower_limit="226.0" upper_limit="336.0"/>
                    <measurement group_id="O3" value="274.0" lower_limit="169.0" upper_limit="337.0"/>
                    <measurement group_id="O4" value="217.0" lower_limit="146.0" upper_limit="340.0"/>
                    <measurement group_id="O5" value="428" lower_limit="NA" upper_limit="NA">There are an insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Limiting Toxicity (DLT) Incidence</title>
        <description>The number of Phase 1 patients who experienced dose limiting toxicities after one cycle (21 days) of study drug.</description>
        <time_frame>Cycle 1 Day 1 to Cycle 1 Day 21</time_frame>
        <population>The dose limiting toxicity (DLT) evaluable population includes all patients who have completed Cycle 1, and who were enrolled while the dose escalation (Phase 1) part of the study was ongoing.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Limiting Toxicity (DLT) Incidence</title>
          <description>The number of Phase 1 patients who experienced dose limiting toxicities after one cycle (21 days) of study drug.</description>
          <population>The dose limiting toxicity (DLT) evaluable population includes all patients who have completed Cycle 1, and who were enrolled while the dose escalation (Phase 1) part of the study was ongoing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>Since an MTD was never reached for any of the rociletinib FB or HBr formulations/doses, a 750 mg BID HBr starting dose was selected based on early efficacy data from Phase 1, and enrollment into Phase 2 was initiated at this dosage. As the Phase 1 efficacy data matured, the recommended dose was adjusted to 625 mg BID based on antitumor activity and safety evaluations.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Determined by Investigator Assessment</title>
        <description>Overall survival was calculated as 1+ the number of days from the first dose of study drug to death due to any cause. Patients without a documented date of death were censored on the date the patient was last known to be alive.</description>
        <time_frame>Cycle 1 Day 1 to date of death, assessed up to 42 months</time_frame>
        <population>The overall number of patients analyzed contains centrally determined T790M positive patients only. There are 2 less patients in the &lt;900 mg BID FB group, and 1 less patient in each of the 500, 625 and 750 mg BID dose groups because they were not followed for OS.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Determined by Investigator Assessment</title>
          <description>Overall survival was calculated as 1+ the number of days from the first dose of study drug to death due to any cause. Patients without a documented date of death were censored on the date the patient was last known to be alive.</description>
          <population>The overall number of patients analyzed contains centrally determined T790M positive patients only. There are 2 less patients in the &lt;900 mg BID FB group, and 1 less patient in each of the 500, 625 and 750 mg BID dose groups because they were not followed for OS.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="175"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="6.3" upper_limit="17.9"/>
                    <measurement group_id="O2" value="23.7" lower_limit="1.4" upper_limit="NA">There are an insufficient number of participants with events.</measurement>
                    <measurement group_id="O3" value="18.5" lower_limit="13.0" upper_limit="NA">There are an insufficient number of participants with events.</measurement>
                    <measurement group_id="O4" value="15.0" lower_limit="12.5" upper_limit="17.3"/>
                    <measurement group_id="O5" value="12.9" lower_limit="9.9" upper_limit="17.7"/>
                    <measurement group_id="O6" value="7.2" lower_limit="2.2" upper_limit="NA">There are an insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)</title>
        <description>Progression-free survival was calculated as the number of days from the date of the first dose of study drug to the date of disease progression or death due to any cause + 1. Patients without a documented event of disease progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment) or date of first dose of study drug if no tumor assessments have been performed. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.</description>
        <time_frame>Cycle 1 Day 1 to End of Treatment, up to approximately 42 months</time_frame>
        <population>The overall number of patients analyzed contains centrally determined T790M positive patients only. There are 2 less patients in the &lt;900 mg BID FB group, and 1 less patient in each of the 500 and 625 mg BID dose groups because they were not followed for PFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)</title>
          <description>Progression-free survival was calculated as the number of days from the date of the first dose of study drug to the date of disease progression or death due to any cause + 1. Patients without a documented event of disease progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment) or date of first dose of study drug if no tumor assessments have been performed. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.</description>
          <population>The overall number of patients analyzed contains centrally determined T790M positive patients only. There are 2 less patients in the &lt;900 mg BID FB group, and 1 less patient in each of the 500 and 625 mg BID dose groups because they were not followed for PFS.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="175"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.3" upper_limit="4.0"/>
                    <measurement group_id="O2" value="10.4" lower_limit="1.4" upper_limit="12.2"/>
                    <measurement group_id="O3" value="5.7" lower_limit="4.2" upper_limit="6.2"/>
                    <measurement group_id="O4" value="5.2" lower_limit="4.1" upper_limit="6.2"/>
                    <measurement group_id="O5" value="4.3" lower_limit="2.9" upper_limit="6.1"/>
                    <measurement group_id="O6" value="7.2" lower_limit="2.2" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Profile of Rociletinib - Cmax</title>
        <description>Cmax = maximum concentration following administration of rociletinib</description>
        <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
        <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 150 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 150 mg once a day (QD).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 200 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 200 mg once a day (QD).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 300 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg once a day (QD).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 450 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 450 mg once a day (QD).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 600 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg once a day (QD).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 900 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg once a day (QD).</description>
          </group>
          <group group_id="O7">
            <title>Rociletinib 100 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 100 mg twice a day (BID).</description>
          </group>
          <group group_id="O8">
            <title>Rociletinib 300 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg twice a day (BID).</description>
          </group>
          <group group_id="O9">
            <title>Rociletinib 600 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg twice a day (BID).</description>
          </group>
          <group group_id="O10">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O11">
            <title>Rociletinib 400 mg TID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 400 mg three times a day (TID).</description>
          </group>
          <group group_id="O12">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O13">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O14">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O15">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Profile of Rociletinib - Cmax</title>
          <description>Cmax = maximum concentration following administration of rociletinib</description>
          <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="18"/>
                <count group_id="O13" value="21"/>
                <count group_id="O14" value="23"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="18"/>
                    <count group_id="O13" value="21"/>
                    <count group_id="O14" value="23"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537" spread="71"/>
                    <measurement group_id="O2" value="533" spread="63"/>
                    <measurement group_id="O3" value="1290" spread="1019"/>
                    <measurement group_id="O4" value="1800" spread="1224"/>
                    <measurement group_id="O5" value="969" spread="824"/>
                    <measurement group_id="O6" value="2470" spread="1482"/>
                    <measurement group_id="O7" value="574" spread="293"/>
                    <measurement group_id="O8" value="706" spread="88"/>
                    <measurement group_id="O9" value="1680" spread="1126"/>
                    <measurement group_id="O10" value="1650" spread="809"/>
                    <measurement group_id="O11" value="704" spread="352"/>
                    <measurement group_id="O12" value="2800" spread="2128"/>
                    <measurement group_id="O13" value="2980" spread="2235"/>
                    <measurement group_id="O14" value="2570" spread="1850"/>
                    <measurement group_id="O15" value="4250" spread="2678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Cmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="16"/>
                    <count group_id="O13" value="16"/>
                    <count group_id="O14" value="22"/>
                    <count group_id="O15" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" spread="188"/>
                    <measurement group_id="O2" value="503" spread="377"/>
                    <measurement group_id="O3" value="1760" spread="1056"/>
                    <measurement group_id="O4" value="942" spread="857"/>
                    <measurement group_id="O5" value="981" spread="343"/>
                    <measurement group_id="O6" value="2200" spread="1100"/>
                    <measurement group_id="O7" value="729" spread="576"/>
                    <measurement group_id="O8" value="647" spread="304"/>
                    <measurement group_id="O9" value="928" spread="95"/>
                    <measurement group_id="O10" value="1510" spread="997"/>
                    <measurement group_id="O11" value="1140" spread="274"/>
                    <measurement group_id="O12" value="2330" spread="1375"/>
                    <measurement group_id="O13" value="3070" spread="2272"/>
                    <measurement group_id="O14" value="2100" spread="1029"/>
                    <measurement group_id="O15" value="2510" spread="728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Profile of Rociletinib - Tmax</title>
        <description>Tmax = time to maximum concentration following administration of rociletinib</description>
        <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
        <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 150 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 150 mg once a day (QD).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 200 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 200 mg once a day (QD).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 300 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg once a day (QD).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 450 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 450 mg once a day (QD).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 600 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg once a day (QD).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 900 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg once a day (QD).</description>
          </group>
          <group group_id="O7">
            <title>Rociletinib 100 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 100 mg twice a day (BID).</description>
          </group>
          <group group_id="O8">
            <title>Rociletinib 300 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg twice a day (BID).</description>
          </group>
          <group group_id="O9">
            <title>Rociletinib 600 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg twice a day (BID).</description>
          </group>
          <group group_id="O10">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O11">
            <title>Rociletinib 400 mg TID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 400 mg three times a day (TID).</description>
          </group>
          <group group_id="O12">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O13">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O14">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O15">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Profile of Rociletinib - Tmax</title>
          <description>Tmax = time to maximum concentration following administration of rociletinib</description>
          <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="18"/>
                <count group_id="O13" value="21"/>
                <count group_id="O14" value="23"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="18"/>
                    <count group_id="O13" value="21"/>
                    <count group_id="O14" value="23"/>
                    <count group_id="O15" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1" upper_limit="2.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O6" value="2.5" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O7" value="2.5" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O8" value="4.0" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O9" value="4.0" lower_limit="2.5" upper_limit="6"/>
                    <measurement group_id="O10" value="4.0" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O11" value="2.5" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O12" value="1.5" lower_limit="0.5" upper_limit="10"/>
                    <measurement group_id="O13" value="2.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O14" value="2.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O15" value="3.25" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="16"/>
                    <count group_id="O13" value="16"/>
                    <count group_id="O14" value="22"/>
                    <count group_id="O15" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.5" upper_limit="6"/>
                    <measurement group_id="O6" value="4.0" lower_limit="1.5" upper_limit="4"/>
                    <measurement group_id="O7" value="2.5" lower_limit="1.5" upper_limit="2.5"/>
                    <measurement group_id="O8" value="1.5" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O9" value="2.5" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O10" value="4" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O11" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O12" value="2.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O13" value="2.5" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O14" value="2.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O15" value="1.5" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Profile of Rociletinib - AUC 0-24</title>
        <description>AUC 0-24 = area under the curve from 0 to 24 hours</description>
        <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
        <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point. AUC was not calculated for patients in the 400 mg TID treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 150 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 150 mg once a day (QD).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 200 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 200 mg once a day (QD).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 300 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg once a day (QD).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 450 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 450 mg once a day (QD).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 600 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg once a day (QD).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 900 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg once a day (QD).</description>
          </group>
          <group group_id="O7">
            <title>Rociletinib 100 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 100 mg twice a day (BID).</description>
          </group>
          <group group_id="O8">
            <title>Rociletinib 300 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg twice a day (BID).</description>
          </group>
          <group group_id="O9">
            <title>Rociletinib 600 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg twice a day (BID).</description>
          </group>
          <group group_id="O10">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O11">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O12">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O13">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O14">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Profile of Rociletinib - AUC 0-24</title>
          <description>AUC 0-24 = area under the curve from 0 to 24 hours</description>
          <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point. AUC was not calculated for patients in the 400 mg TID treatment group.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="21"/>
                <count group_id="O13" value="23"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 AUC 0-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="18"/>
                    <count group_id="O11" value="16"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="19"/>
                    <count group_id="O14" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2900" spread="290"/>
                    <measurement group_id="O2" value="5330" spread="5880"/>
                    <measurement group_id="O3" value="8370" spread="6612"/>
                    <measurement group_id="O4" value="8850" spread="6461"/>
                    <measurement group_id="O5" value="5840" spread="3387"/>
                    <measurement group_id="O6" value="13300" spread="6650"/>
                    <measurement group_id="O7" value="5740" spread="2927"/>
                    <measurement group_id="O8" value="8470" spread="1008"/>
                    <measurement group_id="O9" value="20400" spread="12444"/>
                    <measurement group_id="O10" value="16000" spread="8960"/>
                    <measurement group_id="O11" value="26800" spread="13668"/>
                    <measurement group_id="O12" value="33100" spread="26149"/>
                    <measurement group_id="O13" value="30300" spread="16968"/>
                    <measurement group_id="O14" value="50100" spread="35070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 AUC 0-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="17"/>
                    <count group_id="O11" value="15"/>
                    <count group_id="O12" value="15"/>
                    <count group_id="O13" value="20"/>
                    <count group_id="O14" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1540" spread="970"/>
                    <measurement group_id="O2" value="3510" spread="2620"/>
                    <measurement group_id="O3" value="12100" spread="11616"/>
                    <measurement group_id="O4" value="4490" spread="3817"/>
                    <measurement group_id="O5" value="4800" spread="2256"/>
                    <measurement group_id="O6" value="11500" spread="6555"/>
                    <measurement group_id="O7" value="7100" spread="4189"/>
                    <measurement group_id="O8" value="6080" spread="4560"/>
                    <measurement group_id="O9" value="12100" spread="1404"/>
                    <measurement group_id="O10" value="17500" spread="10675"/>
                    <measurement group_id="O11" value="23700" spread="13035"/>
                    <measurement group_id="O12" value="31700" spread="18386"/>
                    <measurement group_id="O13" value="25800" spread="14190"/>
                    <measurement group_id="O14" value="28200" spread="16638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Profile of Rociletinib - T 1/2</title>
        <description>T 1/2 = elimination half-life following administration of rociletinib</description>
        <time_frame>Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days</time_frame>
        <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point. Elimination half-life was not calculated for patients in the 400 mg TID treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 150 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 150 mg once a day (QD).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 200 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 200 mg once a day (QD).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 300 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg once a day (QD).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 450 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 450 mg once a day (QD).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 600 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg once a day (QD).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 900 mg QD FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg once a day (QD).</description>
          </group>
          <group group_id="O7">
            <title>Rociletinib 100 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 100 mg twice a day (BID).</description>
          </group>
          <group group_id="O8">
            <title>Rociletinib 300 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 300 mg twice a day (BID).</description>
          </group>
          <group group_id="O9">
            <title>Rociletinib 600 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 600 mg twice a day (BID).</description>
          </group>
          <group group_id="O10">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O11">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O12">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O13">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O14">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Profile of Rociletinib - T 1/2</title>
          <description>T 1/2 = elimination half-life following administration of rociletinib</description>
          <population>PK parameters were assessed in a subset of patients treated with rociletinib. For some parameters, the number analyzed at Day 1 and Day 15 differs from the overall number analyzed based on the number of evaluable samples collected at each time point. Elimination half-life was not calculated for patients in the 400 mg TID treatment group.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="18"/>
                <count group_id="O12" value="21"/>
                <count group_id="O13" value="23"/>
                <count group_id="O14" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 T 1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="15"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.6"/>
                    <measurement group_id="O2" value="3.9" spread="2.3"/>
                    <measurement group_id="O3" value="4.6" spread="1.7"/>
                    <measurement group_id="O4" value="3.7" spread="1.1"/>
                    <measurement group_id="O5" value="4.4" spread="0.9"/>
                    <measurement group_id="O6" value="3.5" spread="2.8"/>
                    <measurement group_id="O7" value="3.0" spread="0.8"/>
                    <measurement group_id="O8" value="3.5" spread="1.0"/>
                    <measurement group_id="O9" value="3.6" spread="0.9"/>
                    <measurement group_id="O10" value="2.8" spread="0.7"/>
                    <measurement group_id="O11" value="2.7" spread="0.7"/>
                    <measurement group_id="O12" value="3.5" spread="1.5"/>
                    <measurement group_id="O13" value="3.1" spread="1.5"/>
                    <measurement group_id="O14" value="3.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 T 1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="5"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="14"/>
                    <count group_id="O12" value="13"/>
                    <count group_id="O13" value="19"/>
                    <count group_id="O14" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="3.1"/>
                    <measurement group_id="O2" value="3.5" spread="1.3"/>
                    <measurement group_id="O3" value="4.3" spread="1.2"/>
                    <measurement group_id="O4" value="3.9" spread="2.5"/>
                    <measurement group_id="O5" value="4.1" spread="2.2"/>
                    <measurement group_id="O6" value="3.5" spread=".56"/>
                    <measurement group_id="O7" value="3.1" spread="0.9"/>
                    <measurement group_id="O8" value="2.9" spread="0.7"/>
                    <measurement group_id="O9" value="4.7" spread="3.4"/>
                    <measurement group_id="O10" value="2.7" spread="1.9"/>
                    <measurement group_id="O11" value="3.0" spread="1.6"/>
                    <measurement group_id="O12" value="3.2" spread="0.8"/>
                    <measurement group_id="O13" value="3.6" spread="3.1"/>
                    <measurement group_id="O14" value="3.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect on PK of Rociletinib - Cmax</title>
        <description>Cmax = maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
        <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
        <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
        <group_list>
          <group group_id="O1">
            <title>Cmax Fasting</title>
            <description>Rociletinib 150 mg FB single dose given while fasting</description>
          </group>
          <group group_id="O2">
            <title>Cmax Fed</title>
            <description>Rociletinib 150 mg FB single dose given with a high-fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect on PK of Rociletinib - Cmax</title>
          <description>Cmax = maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
          <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727" spread="354"/>
                    <measurement group_id="O2" value="1873" spread="2570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect on PK of Rociletinib - Tmax</title>
        <description>Tmax = time to maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
        <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
        <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
        <group_list>
          <group group_id="O1">
            <title>Tmax Fasting</title>
            <description>Rociletinib 150 mg FB single dose given while fasting</description>
          </group>
          <group group_id="O2">
            <title>Tmax Fed</title>
            <description>Rociletinib 150 mg FB single dose given with a high-fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect on PK of Rociletinib - Tmax</title>
          <description>Tmax = time to maximum concentration following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
          <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="2.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect on PK of Rociletinib - AUC 0-24</title>
        <description>AUC 0-24 = area under the curve from 0 to 24 hours. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
        <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
        <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules. AUC could not be determined for 1 patient in the Fed arm.</population>
        <group_list>
          <group group_id="O1">
            <title>AUC 0-24 Fasting</title>
            <description>Rociletinib 150 mg FB single dose given while fasting</description>
          </group>
          <group group_id="O2">
            <title>AUC 0-24 Fed</title>
            <description>Rociletinib 150 mg FB single dose given with a high-fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect on PK of Rociletinib - AUC 0-24</title>
          <description>AUC 0-24 = area under the curve from 0 to 24 hours. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
          <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules. AUC could not be determined for 1 patient in the Fed arm.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4780" spread="3625"/>
                    <measurement group_id="O2" value="4455" spread="2256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect on PK of Rociletinib - C24</title>
        <description>C24 = rociletinib plasma concentration at 24 hours post the morning dose. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
        <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
        <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
        <group_list>
          <group group_id="O1">
            <title>C24 Fasting</title>
            <description>Rociletinib 150 mg FB single dose given while fasting</description>
          </group>
          <group group_id="O2">
            <title>C24 Fed</title>
            <description>Rociletinib 150 mg FB single dose given with a high-fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect on PK of Rociletinib - C24</title>
          <description>C24 = rociletinib plasma concentration at 24 hours post the morning dose. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
          <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="22"/>
                    <measurement group_id="O2" value="46.5" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Effect on PK of Rociletinib - T 1/2</title>
        <description>T 1/2 = elimination half-life following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
        <time_frame>Day -7 prior to Cycle 1 Day 1, or approximately 7 days</time_frame>
        <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules. Data did not allow the calculation of half-life with high fat mean in 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>T 1/2 Fasting</title>
            <description>Rociletinib 150 mg FB single dose given while fasting</description>
          </group>
          <group group_id="O2">
            <title>T 1/2 Fed</title>
            <description>Rociletinib 150 mg FB single dose given with a high-fat breakfast</description>
          </group>
        </group_list>
        <measure>
          <title>Food Effect on PK of Rociletinib - T 1/2</title>
          <description>T 1/2 = elimination half-life following administration of rociletinib. The effect of food on rociletinib PK parameters was assessed over a 24-hour period in blood samples from a subset of 3 patients. These patients were given a single dose of rociletinib 150mg FB 1 week prior (Day -7) to the start of continuous daily dosing after fasting. On Day 1 of Cycle 1, patients consumed a high-fat, high-calorie breakfast at the study site prior to receiving rociletinib. On each day, patients underwent blood sampling for PK at the specified time points.</description>
          <population>A subset of 3 patients treated with rociletinib 150 mg FB capsules. Data did not allow the calculation of half-life with high fat mean in 2 patients.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1"/>
                    <measurement group_id="O2" value="3.1" spread="NA">Data for one patient only so standard deviation not applicable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF Values Post Baseline by Daily Dose</title>
        <description>Frequency of QT interval prolongation by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
        <time_frame>Screening to End of Treatment, up to approximately 42 months</time_frame>
        <population>Safety population by daily dose</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF Values Post Baseline by Daily Dose</title>
          <description>Frequency of QT interval prolongation by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
          <population>Safety population by daily dose</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="245"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>QTcF Post-Baseline &lt;450 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>QTcF Post-Baseline 450-480 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>QTcF Post-Baseline 481-500 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>QTcF Post-Baseline &gt;=501 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF Value Change From Baseline</title>
        <description>QTcF value change from baseline by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
        <time_frame>Screening to End of Treatment, up to approximately 42 months</time_frame>
        <population>Safety population by daily dose</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib &lt;900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 900 mg BID FB Capsules</title>
            <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
          </group>
          <group group_id="O3">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O4">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
          <group group_id="O5">
            <title>Rociletinib 750 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
          </group>
          <group group_id="O6">
            <title>Rociletinib 1000 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF Value Change From Baseline</title>
          <description>QTcF value change from baseline by daily dose (corrected using Fridericia's method, QTcF). To evaluate the effects of rociletinib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Baseline, on Cycle 1 Day 1, Cycle 1 Day 15, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.</description>
          <population>Safety population by daily dose</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="245"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>QTcF Change from Baseline &lt;=30 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>QTcF Change from Baseline 30-60 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="101"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>QTcF Change from Baseline &gt;60 msec</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR), Duration of Response (DOR) and Progression-Free Survival (PFS) Per RECIST Version 1.1 as Determined by IRR</title>
        <description>Objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) per RECIST Version 1.1 as determined by independent radiology review (IRR)</description>
        <time_frame>Cycle 1 Day 1 to End of Treatment / End of Follow-up</time_frame>
        <population>Tumor scans were collected for independent evaluation, however ORR, DOR and PFS analyses were not performed by the central reader since the sponsor deemed not necessary following early study termination. Therefore, all IRR outcome measures were not collected and can not be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Rociletinib 500 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
          </group>
          <group group_id="O2">
            <title>Rociletinib 625 mg BID HBr Tablets</title>
            <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR), Duration of Response (DOR) and Progression-Free Survival (PFS) Per RECIST Version 1.1 as Determined by IRR</title>
          <description>Objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) per RECIST Version 1.1 as determined by independent radiology review (IRR)</description>
          <population>Tumor scans were collected for independent evaluation, however ORR, DOR and PFS analyses were not performed by the central reader since the sponsor deemed not necessary following early study termination. Therefore, all IRR outcome measures were not collected and can not be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the date of first dose of study drug and within 28 days after last dose of study drug, or up to approximately 42 months. In addition, study procedure-related AEs that occur after signing of the informed consent form and before first dose of study drug were expected to be reported. Any Serious Adverse Events or Adverse Events of Special Interest were followed until resolution or stabilization, or until patient is lost to follow-up.</time_frame>
      <desc>If a subject experiences the same preferred term (system organ class) multiple times, then the subject will be counted only once for that preferred term (system organ class).</desc>
      <group_list>
        <group group_id="E1">
          <title>Rociletinib &lt;900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose &lt;900 mg twice a day (BID).</description>
        </group>
        <group group_id="E2">
          <title>Rociletinib 900 mg BID FB Capsules</title>
          <description>Rociletinib free base (FB) dose 900 mg twice a day (BID).</description>
        </group>
        <group group_id="E3">
          <title>Rociletinib 500 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID).</description>
        </group>
        <group group_id="E4">
          <title>Rociletinib 625 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID).</description>
        </group>
        <group group_id="E5">
          <title>Rociletinib 750 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID).</description>
        </group>
        <group group_id="E6">
          <title>Rociletinib 1000 mg BID HBr Tablets</title>
          <description>Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="138" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Serratia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malignant pleural infusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basilar artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subgaleal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="244" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="95" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="146" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="138" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="124" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insulin C-peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>QRS axis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="147" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dypnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vi Nguyen</name_or_title>
      <organization>Clovis Oncology</organization>
      <phone>+1 415 915 9982</phone>
      <email>vnguyen@clovisoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

